Business Description
Vogenx Inc. is a Raleigh, North Carolina-based company founded in 2021 that focuses on developing new medicines for metabolic conditions, including post-bariatric hypoglycemia, gastroparesis, and type 1 diabetes. Its drug candidates include Mizagliflozin, VGX-2857, and VGX-001, a human monoclonal antibody targeting type 1 diabetes. The company serves healthcare providers and insurers across the United States.
